Novel therapeutics for the treatment of graft-versus-host disease (Q34841838)

4 August 2017

1 reference

title

Novel therapeutics for the treatment of graft-versus-host disease (English)

1 reference

4 August 2017

David A Jacobsohn

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

published in

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

1271-1280

1 reference

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Pathophysiologic mechanisms of acute graft-vs.-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Drug therapy for acute graft-versus-host disease prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

A humanized antibody that binds to the interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Hydroxychloroquine for the treatment of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

Transplantation of anergic histoincompatible bone marrow allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.9.1271

10.1517/13543784.11.9.1271

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference